利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

284 条记录 (耗时 0.027 秒)

    KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
    58.
    发明公开
    KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF 审中-公开
    犬尿氨酸3单加氧酶抑制剂，药物组合物及其方法使用

    公开(公告)号：EP3049077A2

    公开(公告)日：2016-08-03

    申请号：EP14847911.6

    申请日：2014-09-23

    申请人： CHDI Foundation, Inc.

    发明人： DOMINGUEZ, Celia ,  TOLEDO-SHERMAN, Leticia M. ,  PRIME, Michael ,  MITCHELL, William ,  WENT, Naomi

    IPC分类号： A61K31/381

    CPC分类号： C07D413/12 ,  C07D209/08 ,  C07D213/46 ,  C07D215/18 ,  C07D217/02 ,  C07D231/56 ,  C07D235/08 ,  C07D237/28 ,  C07D239/74 ,  C07D241/42 ,  C07D261/20 ,  C07D263/56 ,  C07D277/24 ,  C07D277/64 ,  C07D307/79 ,  C07D319/18 ,  C07D333/06 ,  C07D333/10 ,  C07D333/28 ,  C07D407/12

    摘要： Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

    摘要翻译： 某些化合物，或其药学上可接受的盐或前药，在被提供。 所以提供了药物组合物，包含至少一种化合物，或其药学上可接受的盐或前药，在描述的和一种或多种药学上可接受的载体。 治疗某些疾病以及响应于KMO活性的抑制的疾病的患者的方法中，其包括施用来搜索患者中的至少一种化合物，或其药学上可接受的盐或前药的量，描述在有效减少体征或症状 疾病或障碍是游离缺失盘。 这些疾病包括神经变性疾病：如亨廷顿病。 如此描述是治疗方法包括施用至少一种化合物，或其药学上可接受的盐或前药，被描述在作为单一活性剂或施用至少一种化合物，或其药学上可接受的盐或前药，在组合的本文所述的一个或 多种其他治疗剂。 这样提供了用于能够KMO抑制活性的筛选化合物的方法。